Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 6:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 193 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Bone Marrow Transplant (BMT) Clear all
Terminated Phase 2 Interventional Results available

Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers

NCT01135329
View directory record Official record
Conditions
Lymphoma, Leukemia, Myelodysplastic Syndrome
Interventions
Fludarabine, Busulfan, Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
6 Months to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 9, 2026, 6:15 AM EDT
Completed Not applicable Interventional

Early Versus Late Bronchoscopy in Bone Marrow Transplantation (BMT) Patients

NCT00846352
View directory record Official record
Conditions
Bone Marrow Transplantation
Interventions
Variation in the time for performing bronchoscopy
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Jackson, Mississippi • Winston-Salem, North Carolina • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 9, 2026, 6:15 AM EDT
Withdrawn Phase 3 Interventional

Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT

NCT03066466
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome
Interventions
Atorvastatin, Methotrexate, Tacrolimus
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 9, 2026, 6:15 AM EDT
Completed Phase 2 Interventional Results available

Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy

NCT00796562
View directory record Official record
Conditions
MDS, Leukemias, Lymphomas
Interventions
Busulfan, Cyclophosphamide, Total body irradiation
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
6 Months to 65 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Oct 9, 2026, 6:15 AM EDT
Recruiting Phase 2 Interventional

Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.

NCT06450925
View directory record Official record
Conditions
Graft Vs Host Disease, Vitamin A Deficiency, Vitamin D Deficiency
Interventions
Vitamin A, Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Tampa, Florida • Buffalo, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 9, 2026, 6:15 AM EDT
Terminated Phase 1 Interventional

Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease

NCT04328714
View directory record Official record
Conditions
Acute Leukemia, Myelodysplastic Syndromes
Interventions
Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells
Drug
Lead sponsor
Edwin Horwitz
Other
Eligibility
1 Year and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 9, 2026, 6:15 AM EDT
Terminated Phase 2 Interventional Results available

Post Transplant Donor Lymphocyte Infusion

NCT00167180
View directory record Official record
Conditions
Leukemia, Myeloid, Chronic, Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome, Leukemia, Lymphocytic, Acute, Leukemia, Lymphocytic, Chronic, AML
Interventions
Donor Lymphocyte Infusion, Induction Chemotherapy
Procedure · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
1 Year to 70 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 9, 2026, 6:15 AM EDT
Completed Phase 2 Interventional Results available

Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma

NCT04402138
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Acalabrutinib
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Denver, Colorado • New Orleans, Louisiana • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 9, 2026, 6:15 AM EDT
Completed Phase 1 Interventional

Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia

NCT02446964
View directory record Official record
Conditions
Adult Acute Lymphoblastic Leukemia in Complete Remission, Acute Myeloid Leukemia in Remission, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Childhood Acute Lymphoblastic Leukemia in Complete Remission
Interventions
Bone Marrow Transplantation, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Total Marrow Irradiation
Procedure · Drug · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
12 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 9, 2026, 6:15 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders

NCT00489281
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Cyclophosphamide, Fludarabine, Mycophenolate mofetil, Sirolimus, Allogeneic bone marrow transplant, Total body irradiation - 200, Levetiracetam, Anti-thymocyte globulin, Total body irradiation - 400
Drug · Procedure · Radiation + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
2 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Oct 9, 2026, 6:15 AM EDT
Terminated Phase 2 Interventional Results available

Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease

NCT01485055
View directory record Official record
Conditions
Graft Versus Host Disease, Steroid Refractory GVHD, Acute GVH Disease
Interventions
Infliximab and Basiliximab
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
6 Months to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
Gainesville, Florida • Columbus, Ohio • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Oct 9, 2026, 6:15 AM EDT
Completed Not applicable Interventional

Feasibility Study of Exercises for Myeloablative Allogeneic Blood and Marrow Transplantation (BMT) Patients

NCT01396031
View directory record Official record
Conditions
Allogenic Disease
Interventions
Physical Therapy
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Oct 9, 2026, 6:15 AM EDT
Recruiting Phase 2 Interventional

Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia

NCT06517641
View directory record Official record
Conditions
Severe Aplastic Anemia
Interventions
Haploidentical donor bone marrow transplant, Unrelated donor bone marrow transplant
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
3 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
25
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 9, 2026, 6:15 AM EDT
Recruiting Early Phase 1 Interventional

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

NCT06398457
View directory record Official record
Conditions
Hematologic Malignancy, Bone Marrow Transplant Rejection, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Acute Lymphoblastic Leukemia (ALL), Adult, Multiple Myeloma, Aplastic Anemia, Lymphoma, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Chronic Myeloid Leukemia, Myelofibrosis
Interventions
Darzalex Faspro (Daratumumab and hyaluronidase-fihj), JH-DSA Semi-Quant Screen and Response Score
Drug · Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 9, 2026, 6:15 AM EDT
Recruiting Phase 1Phase 2 Interventional

Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

NCT03128996
View directory record Official record
Conditions
Severe Sickle Cell Disease, Bone Marrow Failure Syndromes, Metabolic Disorders, Immunologic Disorders, Hemoglobinopathies, Non-malignant Disorders
Interventions
RIC regimen, GVHD prophylaxis regimen
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
1 Day to 21 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2033
U.S. locations
4
States / cities
New Haven, Connecticut • Wilmington, Delaware • Grand Rapids, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 9, 2026, 6:15 AM EDT
Completed Phase 1 Interventional

Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia

NCT01578109
View directory record Official record
Conditions
Acute Myeloid Leukemia With FLT3/ITD Mutation
Interventions
Bone Marrow Transplantation, Sorafenib, Sorafenib Tosylate
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 9, 2026, 6:15 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Stem Cell Transplant for Bone Marrow Failure Syndromes

NCT00176878
View directory record Official record
Conditions
Diamond-Blackfan Anemia, Kostmann's Neutropenia, Shwachman-Diamond Syndrome
Interventions
Stem cell transplant, Fludarabine monophosphate, Total lymphoid irradiation, Busulfan, anti-thymocyte globulin
Procedure · Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 35 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 9, 2026, 6:15 AM EDT
Completed Phase 2 Interventional

Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)

NCT04965597
View directory record Official record
Conditions
Bone Marrow Failure Syndrome, Congenital Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia, Hereditary Sideroblastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Shwachman-Diamond Syndrome, Hematologic Neoplasm With Germline GATA2 Mutation, Hematologic Neoplasm With Germline SAMD9 Mutation, Hematologic Neoplasm With Germline SAMD9L Mutation
Interventions
Treosulfan, Fludarabine Phosphate, Tacrolimus, Methotrexate, Lapine T-Lymphocyte Immune Globulin, Peripheral Blood Stem Cell Transplantation, Allogeneic Bone Marrow Transplantation, Quality-of-Life Assessment, Echocardiography, Multigated Acquisition Scan, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection, X-Ray Imaging, Computed Tomography
Drug · Biological · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
1 Year to 49 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
24
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 9, 2026, 6:15 AM EDT
Completed Early Phase 1 Interventional Results available

Donor Stem Cell Transplantation for Congenital Immunodeficiencies

NCT00426517
View directory record Official record
Conditions
Inherited Immune Deficiencies
Interventions
Campath 1H, Busulfan, Horse Anti-human Thymocyte Globulin (h-ATG), Total Body Irradiation (TBI), Sirolimus or equivalent based on response
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 40 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 9, 2026, 6:15 AM EDT
Completed Not applicable Interventional

Nutritional Assessment Intervention to Improve Cancer-Related Fatigue

NCT00507260
View directory record Official record
Conditions
Leukemia, Lymphoma, Fatigue
Interventions
Food Record, Nutritional Consults
Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 24, 2014 · Synced Oct 9, 2026, 6:15 AM EDT
Completed Not applicable Interventional

Oncology Care at Home for BMT and CAR-T

NCT05826288
View directory record Official record
Conditions
Leukemia
Interventions
BioIntelliSense BioButton Rechargable, Memora Health two-way patient engagement platform provided by RC
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 9, 2026, 6:15 AM EDT
Completed Phase 2 Interventional Results available

Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)

NCT02766465
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Busulfan, Fludarabine, r-ATG, Hematopoietic Cell Transplant, Tacrolimus, Methotrexate, Standard of Care, Alemtuzumab, Total Body Irradiation (TBI), Sirolimus, Melphalan, G-CSF
Drug · Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
15 Years to 40 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
35
States / cities
Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 9, 2026, 6:15 AM EDT
Completed Phase 1 Interventional

Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD)

NCT00854139
View directory record Official record
Conditions
Multiple Myeloma, End Stage Renal Disease
Interventions
Cyclophosphamide, anti-thymocyte globulin, Kidney transplant, Thymic irradiation, Bone marrow transplant from a related donor
Drug · Procedure · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 9, 2026, 6:15 AM EDT
Completed Not applicable Interventional

Stanford Letter or Traditional Advance Directive in Advance Care Planning in Patients Undergoing Bone Marrow Transplant

NCT03028961
View directory record Official record
Conditions
Advance Directives, Bone Marrow Transplant
Interventions
Stanford Letter, Interview, Questionnaire Administration, CA Advance Health Care Directive Form
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 100 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 9, 2026, 6:15 AM EDT